BioSpace News Archive

HUTCHMED Limited announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration, on January 1, 2024 the updated National Reimbursement Drug List will continue to include ELUNATE® and SULANDA® at the same terms as the current two-year agreement.

Innovent Biologics, Inc. announces that, the National Reimbursement Drug List has been updated to renew and include the seventh indication of PD-1 inhibitor TYVYT® in negotiation list, and include the eighth indication of BYVASDA® in general list.

MAPS Public Benefit Corporation (“MAPS PBC”) announced the submission of a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for MDMA (midomafetamine capsules) used in combination with psychological intervention, which includes psychotherapy, or talk therapy, and other supportive services provided by a qualified healthcare provider.

Intensity Therapeutics, Inc. today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO).

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment.

Ankyra Therapeutics today announced results from a preclinical study demonstrating potent anti-tumor activity of its lead program ANK-101 were published in the December issue of the Journal of Clinical Investigation Insight (JCI Insight).

Premier, Inc.’s PINC AI™ Applied Sciences (PAS) and TFS HealthScience are announcing a landmark collaboration to accelerate global clinical trials and research innovation, improve patient outcomes and reduce health disparities.

Coya Therapeutics, Inc. announced today the closing of the sale of an aggregate of 4,370,382 shares of its common stock at a purchase price of $6.06 per share of common stock, in a private placement priced at-the-market under Nasdaq rules.

Ainos, Inc. today announced that, as previously authorized by its shareholders, the Company is implementing a consolidation (reverse stock split) of its outstanding shares of common stock.

Breaking its Silence and Emerging from Stealth mode. Envoya, a Pioneering Company in the Biotechnology Sector, Today Announces the Soft Launch of its Revolutionary Drug Delivery Platform for Gene Therapy.